In the semaglutide group, patients lost an average of 26.7% of their total body weight and 86.3% of their excess weight
10.1136/bmjopen-2018-02800731147367 190 Kawasoe S, Kubozono T, Yoshifuku S, et al
Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing
He also found several fitness-community friends who'd tried BPC-157 for soft-tissue issues, a torn rotator cuff, chronic knee inflammation from years of running, and reported favorable results, though nothing that sounded like a cure
They can determine which Ozempic alternative (if any) could be a good option and offer guidance on how to transition from one medication to the other
The practical takeaway: if the Wegovy pill's administration requirements feel like a barrier for you, it may be worth waiting to see how orforglipron's FDA review unfolds over the next 12 months before making a long-term treatment decision